Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention
Conditions
Ovarian Cancer
Conditions: official terms
Ovarian Neoplasms
Study Type
Interventional
Study Phase
N/A
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Intervention
Name: Group Session Type: Behavioral
Name: Telephone Coaching Session Type: Behavioral
Name: Webinar Type: Behavioral
Overall Status
Recruiting
Summary
This research study is evaluating an educational intervention for women who have experienced changes in sexual function after treatment for ovarian cancer.
Detailed Description
The purpose of this research is to study the effectiveness of an educational intervention for women who have experienced changes in sexual function after treatment for ovarian cancer. The aim is to develop an effective intervention to help women manage these changes and restore sexual health and functioning. This study consists of attending a group educational session followed by a one-on-one telephone counseling session.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Women diagnosed with Stage1-IV ovarian cancer

- Prognosis of at least one year to live (as assessed by provider)

- Endorsement of at least one sexual symptom (see Appendix A for eligibility screening)

- English speaking

- Signed informed consent

Exclusion Criteria:

- History of pelvic radiation

- Cognitive impairment which would interfere with the ability to participate in the study (as assessed by provider)
Locations
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Status: Recruiting
Contact: Sharon Bober, Ph.D - 617-632-6547 - sharon_bober@dfci.harvard.edu
Massachusetts General Hospital
Boston, Massachusetts, United States
Status: Recruiting
Contact: Carolyn Krasner, MD - 617-726-1941 - pdicicco@partners.org
Start Date
November 2014
Completion Date
October 2019
Sponsors
Dana-Farber Cancer Institute
Source
Dana-Farber Cancer Institute
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page